SCHEDULE: Matinas BioPharma: Stern Ups Stake via Warrant Exercises

Adam K. Stern and affiliated entities have updated their Schedule 13D filing to reflect the exercise of warrants and the acquisition of new warrants in Matinas BioPharma Holdings, Inc., increasing beneficial ownership.

Summary

• Adam K. Stern and affiliated entities, including Sanitam Partners LLC, AKSLP, and SternAegis DBP, have filed an amendment to their Schedule 13D regarding Matinas BioPharma Holdings, Inc.
• The filing details the exercise of existing warrants and the acquisition of new warrants as part of an inducement offer from the company.
• Specifically, AKSLP exercised warrants for 344,710 shares and SternAegis DBP exercised warrants for 630,335 shares, both at $0.35 per share.
• These exercises were in exchange for new warrants with similar terms, exercisable upon stockholder approval.
• Ownership percentages are subject to beneficial ownership limitations (4.99% or 9.99%).
• The total beneficial ownership for Adam K. Stern is reported as 2,972,524 shares, representing 9.99% of the class, after accounting for ownership blockers.
• ThinkEquity LLC acted as the solicitation agent for these warrant exercises, receiving a fee and Solicitation Agent Warrants.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily reflecting routine updates on warrant exercises and related agreements rather than significant new strategic developments or financial performance changes.

Positives

• Increased beneficial ownership by a significant stakeholder (Adam K. Stern) through warrant exercises, potentially indicating confidence in the company's future.
• The company is actively engaging with warrant holders through inducement offers, which could lead to a stronger balance sheet if cash exercises are significant.
• The exercise price of $0.35 per share for both existing and new warrants provides a clear valuation reference point.

Negatives

• The issuance of new warrants is contingent on stockholder approval, creating uncertainty.
• The beneficial ownership limitations (4.99%/9.99%) restrict the ability of reporting persons to increase their stake beyond these thresholds without further action.
• The company is paying a 10% cash fee and issuing additional warrants to a solicitation agent, which adds to transaction costs.

Risks

• Failure to obtain Inducement Stockholder Approval for the issuance of shares underlying the New Warrants could prevent their exercise.
• The beneficial ownership limitations may prevent the reporting persons from fully exercising their rights or increasing their stake as desired.
• The reliance on warrant exercises and potential future stock issuances for capital could dilute existing shareholders if not managed effectively.

Future Outlook

The future outlook is tied to obtaining stockholder approval for the issuance of shares underlying the New Warrants. The exercise of these warrants at $0.35 per share is a key event that will impact the company's capital structure and potentially its cash position.

Management Comments

• The reporting persons disclaim beneficial ownership of securities except to the extent of their equity interest.
• The percentage of shares reported owned reflects the application of ownership blockers (4.99% and 9.99%).
• Holders of Preferred Stock are entitled to vote with Common Stock holders, with each share of Preferred Stock having votes based on its stated value divided by $0.6393.

Industry Context

StockSavvy.ai notes that warrant exercises and the issuance of new securities are common strategies for biotechnology companies, particularly those in development stages, to raise capital or incentivize existing stakeholders. The involvement of a solicitation agent like ThinkEquity LLC is also typical in such transactions to facilitate engagement with warrant holders.

Comparison to Industry Standards

• The fee structure of 10% cash and warrants to a solicitation agent is within the typical range for such services in the biotech sector, though on the higher end.
• The inducement offer structure, requiring stockholder approval for new warrants, is a standard practice to comply with exchange listing rules and investor protection measures.
• The beneficial ownership limitations (4.99%/9.99%) are common provisions in warrant agreements to manage potential control issues and regulatory filings.

Related Party Transactions

• Distribution of Warrants and Preferred Stock by Sanitam Partners LLC to its members, including AKSLP.
• Adam K. Stern has voting and investment control over securities held by AKSLP and AKS, though he disclaims beneficial ownership beyond his equity interest.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of shares underlying the New Warrants, but also potential for increased capital for the company.
• Warrant Holders: Opportunity to exercise existing warrants and receive new warrants, subject to terms and conditions.
• Management: Facilitation of capital raising and potential increase in ownership for key stakeholders like Adam K. Stern.

Next Steps

• Obtain Inducement Stockholder Approval for the issuance of shares of Common Stock underlying the New Warrants.
• Exercise of New Warrants by holders, subject to beneficial ownership limitations.
• Potential future capital infusion for the company if cash exercises are substantial.

Key Dates

Keywords

Matinas BioPharma, Schedule 13D, Warrant Exercise, Adam K Stern, Sanitam Partners, Inducement Offer, ThinkEquity LLC, Beneficial Ownership